|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contributor Cindy H. Dubin speaks with several innovative CDMOs to discuss their formulation development and manufacturing capabilities (as well as shifting strategies) for bio/pharma companies of all sizes.
|
|
|
Iain MacGilp, PhD, says the path to delivering stable, apparently simple solution, suspension, or emulsion formulations is multi-faceted and requires a constant focus on key control measures through pre-formulation development to commercialization.
|
|
|
Patrick Le Gal explains how his company deployed a quality by design approach to manage all the unavoidable competing requirements and to propose a solution that balances performance, robustness, and usability.
|
|
|
This e-Book highlights some of the innovators and innovations in the respiratory sector, addresses the importance of end users in the device development process, and presents recent advancements in improving patient adherence.
|
|
|
Hillel Cohen, PhD, outlines the evolution of biosimilar approvals and describes the process of analytical and clinical testing followed in the development of a biosimilar, with use of data from the scientific literature.
|
|
|
Paulo Lino, PhD, and João Henriques discuss the main development goals and present a framework for a streamlined development of amorphous solid dispersion formulations by spray drying.
|
|
|
Jim Huang, PhD, says more than 50% of approved drugs on the market contain poorly water soluble APIs, which typically are associated with poor bioavailability, suboptimal drug delivery, ineffective drug efficacy, and side effects, and this creates a huge opportunity in generating 505(b)(2) products.
|
|
|
Rafael Miñana, PhD, explores the benefits of preclinical outsourcing, the value of zebrafish as an alternative model, as well as the challenges and opportunities of managing a highly diversified portfolio and providing customized solutions.
|
|
|
Andrew Leber, PhD, Raquel Hontecillas, PhD, and Josep Bassaganya-Riera, PhD, say current IBD therapeutics have mediocre efficacy, poor maintenance of response, and damaging side effects, including cancer, infection, and death, resulting in an unmet clinical need for safer and more effective oral therapeutics.
|
|
|
|
|
|
|
|
|

Founded in 1897, BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to healthcare. BD’s drug delivery systems are designed to protect, package, and deliver drug therapies and to maximize healthcare worker and patient safety. Click here for more.
|
|
|
|
|
|
 |
|
The contract calls for Atlas to sell stabilized and functionalized silver nanoparticles to Gem Labs for use in the manufacture of one of Gem Labs proprietary products.
|
|
 |
|
LabTwin GmbH, the world’s first voice and AI-powered digital lab assistant, recently announced partnerships with CA-based life science shared lab facilities Bonneville Labs and Lab Launch to……
|
|
 |
|
Quotient Sciences and global investment firm Permira recently announced that a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in…….
|
|
 |
|
Pfenex Inc. and Arcellx, Inc. recently announced a Development, Evaluation, and License agreement under which Arcellx gains access to the proprietary Pfenex Expression Technology platform to advance……
|
|
 |
|
Whether it is meeting the needs of a rapidly aging market, blocking drug counterfeiters, or differentiating your pharmaceutical product in the market, a secondary packaging program is an important factor in………
|
|
|
|
|
Upcoming eNewsletter Features:
August 14 – Analytical Testing
August 21 – ODT/Fast Dissolve
|
|
|
|
|
|
|
|